A. Klettner and J. Roider Pages 1127 - 1135 ( 9 )
The neutralization of VEGF is the current treatment of choice for age-related macular degeneration. Current approaches include anti-VEGF-antibodies and – Fab Fragments, aptamers, soluble receptors (Traps) and siRNA. The molecular properties of VEGF and its antagonists are reviewed and the pathways of action of these substances are discussed.
VEGF, ranibizumab, lucentis, AMD, pegaptanib, VEGF-trap
UK S-H, Department of Ophthalmology, Campus Kiel, Hegewischstr. 2, 24105 Kiel, Germany.